Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Umraniye Education and Research Hospital | OTHER_GOV |
| Gaziantep City Hospital | OTHER |
| Namik Kemal University School of Medicine, Tekirdag | OTHER |
Not provided
Not provided
Not provided
Not provided
This multicenter, prospective cohort study aims to identify clinical and demographic predictors that influence the success of greater occipital nerve (GON) block in patients with migraine.
Patients will be evaluated at baseline, on each injection day, and at one- and three-month follow-ups. Study parameters include demographics, migraine type and duration, comorbidities, headache characteristics, treatment history, and validated outcome measures such as the Numeric Rating Scale (NRS), Headache Impact Test-6 (HIT-6), and Global Rating of Change (GRoC).
The goal is to establish predictive factors of treatment success in order to optimize patient selection and contribute robust multicenter evidence to individualized migraine management
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| GON Block Group | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Greater Occipital Nerve (GON) Blockade | Procedure | The greater occipital nerve block (GONB) will be performed using anatomical landmarks (distal approach). The injection point is located at the medial one-third of the line between the external occipital protuberance and the mastoid process. A 26-gauge insulin needle will be used for the procedure. The block will be administered bilaterally with 0.5% bupivacaine, 1.5 ml per side (total 3 ml). The intervention will be repeated once weekly for a total of four sessions |
| Measure | Description | Time Frame |
|---|---|---|
| Number of days with headache | Baseline,1st month and 3rd month |
| Measure | Description | Time Frame |
|---|---|---|
| The 6-Item Headache Impact Test (HIT-6) | The 6-Item Headache Impact Test (HIT-6) is a brief, validated questionnaire that assesses the adverse impact of headaches on daily functioning, with higher scores indicating greater impact. | Baseline,1st month and 3rd month |
| Global Rating of Change (GROC) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Tuba Tanyel Saraçoğlu | Contact | +90 212 909 60 00 | tuba.saracoglu1@saglik.gov.tr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Başakşehir Çam and Sakura City Hospital | Istanbul | Turkey (Türkiye) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008881 | Migraine Disorders |
| ID | Term |
|---|---|
| D051270 | Headache Disorders, Primary |
| D020773 | Headache Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| Bakırçay University, Faculty of Medicine |
| UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
|
The Global Rating of Change (GROC) is a patient-reported scale that measures perceived change in health status over time, typically ranging from very much worse to very much improved. |
| 1st month and 3rd month |
| Numeric Rating Scale | A simple and widely used tool to assess pain intensity, where patients rate their pain on a scale from 0 to 10, with 0 meaning 'no pain' and 10 meaning 'the worst pain imaginable | Baseline,1st month and 3rd month |
| Number of migraine attacks | Baseline, 1st month and 3rd month |
| Duration of migraine attacks | Baseline, 1st month and 3rd month |
| Analgesic consumption | Baseline, 1st month and 3rd month |
| D009422 | Nervous System Diseases |